Clinical Trial Detail

NCT ID NCT01497444
Title Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors North Central Cancer Treatment Group

liver cancer

kidney cancer


Evofosfamide + Sorafenib

Age Groups: senior adult

No variant requirements are available.